Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
about
The use of laboratory tests in the diagnosis of SLEHypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients.Lupus pathobiology based on genomics.Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively.Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively.A long-term immunological study of childhood onset systemic lupus erythematosusPredictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus.Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosusCell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside.Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease.Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity.Complement and systemic lupus erythematosus.Lowering anti-dsDNA antibodies--what's new?Complement and lupus: old concepts and new directions.The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observationMycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk.Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus.Clinical trial design in systemic lupus erythematosus: lessons learned and future directions.Lupus nephritis: a review of the current pharmacological treatments.Quantitation of autoantibodies in systemic autoimmune diseases: clinically useful?Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus.Why can't we find a new treatment for SLE?Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy.Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.Analysis of three new idiotypes on human monoclonal autoantibodies.Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy.Systemic lupus erythematosus biomarkers: the challenging quest.Serological tests in the assessment of disease activity in systemic lupus erythematosus.Serological markers of disease activity in systemic lupus erythematosus.Serum level of proximal renal tubular epithelial cell-binding immunoglobulin G in patients with lupus nephritis.Use of recombinant RNP peptides 70K and A in an ELISA for measurement of antibodies in mixed connective tissue disease: a longitudinal follow up of 18 patients.Significance of low molecular weight C1q in systemic lupus erythematosus.Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review.A surge in anti-dsDNA titer predicts a severe lupus flare within six months.Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period.
P2860
Q24682977-12FA3696-4CD7-4B28-8221-477AA8536B9FQ33363684-0F076976-CB67-4ABE-9024-19B5CB836746Q33364409-A50A389F-80C7-40C1-8573-F9D4DF2474E0Q33561741-4832AA7A-D7ED-4E7C-82AB-E9D4DF758D24Q33561747-2C5A4D68-B7B5-47CA-A179-73E0FE629A30Q33564212-D0D1CF99-C6C7-49DA-97E8-2D9D7A524ADBQ33565963-801DD10D-54CA-4FF6-92E5-FA8138845A14Q33599086-5F7872B2-A31E-4221-B5BF-B23D56E051A5Q33723371-F9348C7A-489C-4E31-B180-D5D526B6ECBBQ33743791-AF873583-707D-4112-AA79-A1A5C938E8B9Q34555048-FBFEDFE8-3CD4-4EF7-9029-5AA980B6ECF7Q34720014-2A099E40-C1B9-48F6-AF67-164F833462A5Q34731255-36AAC02D-EC11-466E-9ACB-FA030588FE4CQ35045927-CFCBF2A0-EAF2-441D-982E-3E7C8E1B1986Q35222830-EA5AADB1-09AE-45FF-B1F7-990926CA809AQ35546997-70835F59-CE63-439C-92A8-358DF6450BD9Q35552758-EC809234-CFAF-432C-8BAA-5F013035F435Q35555256-B339A258-147C-44EC-8ABE-ECD6B58AE098Q35824467-AFC63266-637D-49B7-965C-AE749BFCC949Q35824541-7D1D197E-E645-4A43-80C5-3E81E71BBDE6Q35925513-82021B9D-6B1B-431D-B734-BBA66ACECE74Q36560767-588521C0-CEA9-427F-9970-3BDFE7851176Q36674267-D77C3ED0-1607-45B7-8507-E509063C3534Q37236049-64E332A9-B02A-4F5E-8709-782572865F7CQ38176594-6E1BA4A0-C3C2-4734-AB99-EA912083A501Q38205079-222C3905-C653-4838-A792-7831C82C97E0Q38290823-11782E76-9668-4D9C-ACAA-3DB7C8740F78Q38453113-F3FBA63D-1317-41E6-A85B-F0C40A031B07Q39053118-76577B93-7048-468F-82B7-C3FAD9F858EDQ39759636-72CE2A22-FEE5-4256-92EE-5D7B8F51051CQ40552933-45780127-19C5-4212-B614-59E4E475BA51Q40649478-E4B1BFFE-7CC8-42B0-9392-63683724FB36Q41223515-6F4EC904-971A-4FED-8DA4-993F95CB7A8AQ41227270-158D68BD-68F8-43CB-917B-53728820AD28Q42634173-42EBD760-56F9-4D09-B644-513870118EF5Q43677777-34725BED-51C3-438D-8CC5-AD9D72D18821Q43772904-ABC312CD-FF04-4A17-83C8-8C0A2D77A736Q43772908-A9E18166-9BA2-41B3-A417-D6376BA665E1Q44305349-AB0E7828-48BB-4207-8597-9C31F640C426Q44520690-BFBC3423-15A8-4467-B6F0-5DD8AE4CE756
P2860
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
description
1986 nî lūn-bûn
@nan
1986 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
@ast
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
@en
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
@nl
type
label
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
@ast
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
@en
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
@nl
prefLabel
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
@ast
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
@en
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
@nl
P2093
P2860
P356
P1476
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
@en
P2093
Bronsveld W
Groenwold J
P2860
P304
P356
10.1136/ARD.45.5.359
P407
P577
1986-05-01T00:00:00Z